Related Experiment Videos

[New methods in early diagnosis of a cardiomyopathy caused by adriamycin]

Onkologie
|December 1, 1978
PubMed

Insights

Early detection of Adriamycin-induced cardiomyopathy is crucial. Systolic time intervals offer a simple, accurate method for identifying this cardiac condition, unlike chest X-ray or ECG.

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Adriamycin (doxorubicin) is a potent cytostatic drug used in cancer treatment.
  • High doses of Adriamycin can lead to dose-dependent congestive (dilative) cardiomyopathy.
  • Early detection of Adriamycin-induced cardiomyopathy is vital to prevent irreversible cardiac damage.

Purpose of the Study:

  • To evaluate diagnostic methods for the early detection of Adriamycin-induced cardiomyopathy in patients.
  • To compare the efficacy of various diagnostic tools, including chest X-ray, ECG, echocardiography, radiocardiography, and systolic time intervals.

Main Methods:

  • The study involved 120 patients treated with Adriamycin.
  • Diagnostic assessments included chest X-ray, electrocardiogram (ECG), echocardiography, radiocardiography (with minimal cardiac transit time determination), and systolic time intervals.
  • Data were analyzed to determine the sensitivity and specificity of each method for early cardiomyopathy detection.

Main Results:

  • Chest X-ray and ECG were found to be unsuitable for the early detection of Adriamycin-induced cardiomyopathy.
  • Echocardiography and radiocardiography, including minimal cardiac transit time, allowed for relatively early diagnosis.
  • Determination of systolic time intervals proved to be a simple, economical, and exact method for early recognition.

Conclusions:

  • Systolic time intervals are a highly effective and accessible tool for the early diagnosis of Adriamycin-induced cardiomyopathy.
  • Echocardiography and radiocardiography also aid in early detection.
  • Routine monitoring using systolic time intervals is recommended for patients receiving Adriamycin therapy.

Related Concept Videos